🇺🇸 FDA
Pipeline program

Imatinib Mesylate

IRAS ID: 274093

Phase 2 small_molecule active

Quick answer

Imatinib Mesylate for Pulmonary Arterial Hypertension is a Phase 2 program (small_molecule) at UNITED THERAPEUTICS Corp with 1 ClinicalTrials.gov record(s).

Program details

Company
UNITED THERAPEUTICS Corp
Indication
Pulmonary Arterial Hypertension
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials